4SCAR-276 / SZGIMI - LARVOL DELTA

Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: May 2024 ➔ Dec 2030 | Trial primary completion date: May 2023 ➔ Dec 2029

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CD276